Helen Torley sold $3.4M of HALO
PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC.. 50,000 shares at an average of $67.40, traded Jun 1, 2026, filed Jun 3, 2026.
Score components
- +25RoleCEO
- +25Trade size$3.4M at market
- 0Share of holdings soldSold 6.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001159036-26-000074, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $12.07 | $241k | 787,780 | Jun 3, 2026 |
| Jun 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1,610 | $66.39 | $107k | 786,170 | Jun 3, 2026 |
| Jun 1, 2026 | SOpen-market sale Common Stock10b5-1 | -12,989 | $67.41 | $876k | 773,181 | Jun 3, 2026 |
| Jun 1, 2026 | SOpen-market sale Common Stock10b5-1 | -5,401 | $68.35 | $369k | 767,780 | Jun 3, 2026 |
| Jun 2, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $12.07 | $241k | 787,780 | Jun 3, 2026 |
| Jun 2, 2026 | SOpen-market sale Common Stock10b5-1 | -16,600 | $66.31 | $1.1M | 771,180 | Jun 3, 2026 |
| Jun 2, 2026 | SOpen-market sale Common Stock10b5-1 | -3,400 | $66.75 | $227k | 767,780 | Jun 3, 2026 |
| Jun 3, 2026 | MOption exercise Common Stock10b5-1 | +10,000 | $12.07 | $121k | 777,780 | Jun 3, 2026 |
| Jun 3, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $66.37 | $27k | 777,380 | Jun 3, 2026 |
| Jun 3, 2026 | SOpen-market sale Common Stock10b5-1 | -1,500 | $67.68 | $102k | 775,880 | Jun 3, 2026 |
| Jun 3, 2026 | SOpen-market sale Common Stock10b5-1 | -2,000 | $68.74 | $137k | 773,880 | Jun 3, 2026 |
| Jun 3, 2026 | SOpen-market sale Common Stock10b5-1 | -6,100 | $69.69 | $425k | 767,780 | Jun 3, 2026 |
| Jun 1, 2026 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $12.07 | $241k | 31,923 | Jun 3, 2026 |
| Jun 2, 2026 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $12.07 | $241k | 11,923 | Jun 3, 2026 |
| Jun 3, 2026 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -10,000 | $12.07 | $121k | 1,923 | Jun 3, 2026 |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 22Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $568k 5,230 shares | -9% | |
| 33Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $2.0M 18,996 shares | -24% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.4M 60,000 shares | -8% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.3M 60,000 shares | -8% | |
| 14Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $167k 1,626 shares | -4% | |
| 16Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $153k 1,923 shares | -0% | |
| 20Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $125k 1,625 shares | -4% | |
| 24Weak | HALOZYME THERAPEUTICS, INC. | Mahesh Krishnan director | $548k 7,304 shares | -34% | |
| 13Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $108k 1,625 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.